Lawrence Eichenfield - 05 Jun 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: VRCA
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 16:45:11 UTC
Previous filing: 22 Aug 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Eichenfield Lawrence	Director	C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER	/s/ Mark Ballantyne, Attorney-in-Fact	09 Jun 2025	0001814892

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRCA	Stock Option (right to buy)	Award	$0	+20,000		$0.000000	20,000	05 Jun 2025	Common Stock	20,000	$0.5800	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.